{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:56:37Z","timestamp":1794333397152,"version":"4.9.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.ctrv.2011.06.011","type":"journal-article","created":{"date-parts":[[2011,8,2]],"date-time":"2011-08-02T19:29:00Z","timestamp":1312313340000},"page":"284-291","source":"Crossref","is-referenced-by-count":76,"title":["Skeletal metastasis in renal cell carcinoma: Current and future management options"],"prefix":"10.1016","volume":"38","author":[{"given":"Steven L.","family":"Wood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet E.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2011.06.011_b0005","unstructured":"Ferlay JBF, Pisani P, Parkin DM. Cancer incidence, mortality and prevalence worldwide. \u201cGLOBOCAN2002\u201d IARC CancerBase No. 5 Version 2.0, 2000."},{"key":"10.1016\/j.ctrv.2011.06.011_b0010","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.bone.2010.09.008","article-title":"Skeletal complications and survival in renal cancer patients with bone metastases","volume":"48","author":"Woodward","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.ctrv.2011.06.011_b0015","unstructured":"National Cancer Institute, SEER Statistical Fact Sheets, <http:\/\/seer.cancer\/gov\/statfacts\/index.html>."},{"key":"10.1016\/j.ctrv.2011.06.011_b0020","first-page":"379","article-title":"The skeletal metastatic complications of renal cell carcinoma","volume":"19","author":"Zekri","year":"2001","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ctrv.2011.06.011_b0025","doi-asserted-by":"crossref","first-page":"s6397","DOI":"10.1158\/1078-0432.CCR-040030","article-title":"Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid","volume":"10","author":"Lipton","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2011.06.011_b0030","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s12253-009-9184-7","article-title":"Prognostic factors and survival of renal clear cell carcinoma patients with bone metastases","volume":"16","author":"Szendroi","year":"2010","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.ctrv.2011.06.011_b0035","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1743-7563.2010.01277.x","article-title":"New systemic treatment options for metastatic renal-cell carcinoma in the era of targeted therapies","volume":"6","author":"Tan","year":"2010","journal-title":"Asia-Pacific J Clin Oncol"},{"key":"10.1016\/j.ctrv.2011.06.011_b0040","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ctrv.2011.06.011_b0045","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2011.06.011_b0050","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2165\/00024669-200302040-00005","article-title":"Metastatic bone disease. Developing strategies to optimise management","volume":"2","author":"Brown","year":"2003","journal-title":"Am J Cancer"},{"issue":"Suppl 3","key":"10.1016\/j.ctrv.2011.06.011_b0055","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ctrv.2005.09.004","article-title":"Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence","volume":"31","author":"Smith","year":"2005","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2011.06.011_b0060","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s10585-011-9379-7","article-title":"Treatment outcome and prognostic factors in renal cell cancer patients with bone metastasis","volume":"28","author":"Yuasa","year":"2011","journal-title":"Clin Exp Metastasis."},{"key":"10.1016\/j.ctrv.2011.06.011_b0065","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1158\/1535-7163.MCT-07-0234","article-title":"Molecular biology of bone metastasis","volume":"6","author":"Kingsley","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2011.06.011_b0070","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/path.2567","article-title":"Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinoma","volume":"218","author":"Mikami","year":"2009","journal-title":"J Pathol"},{"key":"10.1016\/j.ctrv.2011.06.011_b0075","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2011.06.011_b0080","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1259\/bjr\/52773262","article-title":"Comparison of whole body MRI and bone scintigraphy in the detection of bone metastases in renal cancer","volume":"82","author":"Sohaib","year":"2009","journal-title":"Brit J Radiol"},{"key":"10.1016\/j.ctrv.2011.06.011_b0085","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0094-0143(21)00636-4","article-title":"Management of distant solitary recurrence in the patient with renal cancer. Contralateral kidney and other sites","volume":"21","author":"Kozlowski","year":"1994","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.ctrv.2011.06.011_b0090","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/CCO.0b013e3282f8b02b","article-title":"Recent developments in urologic oncology: positron emission tomography molecular imaging","volume":"20","author":"Bouchlouche","year":"2008","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.ctrv.2011.06.011_b0095","doi-asserted-by":"crossref","first-page":"360","DOI":"10.2214\/AJR.07.2077","article-title":"Imaging in metastatic renal cell carcinoma","volume":"189","author":"Griffin","year":"2007","journal-title":"AJR"},{"key":"10.1016\/j.ctrv.2011.06.011_b0100","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1007\/s00259-006-0362-5","article-title":"[1-(11)C]acetate uptake is not increased in renal cell carcinoma","volume":"34","author":"Kotzerke","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ctrv.2011.06.011_b0105","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1089\/cbr.2008.0536","article-title":"Synthesis of 99mTc-DOTMP and its preclinical evaluation as a multidentate imaging agent for skeletal metastases","volume":"24","author":"Datta","year":"2009","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.ctrv.2011.06.011_b0110","doi-asserted-by":"crossref","unstructured":"Glaudemans AWJM, Lam MGEH, Veltman NC, Dierckx RAJO, Signore A. The contribution of nuclear medicine in the diagnosis of bone metastases. In: Kardamakis D, Vassiliou V, Chow E, editors. Bone metastases: a translational and clinical approach. Springer; 2009. p. 137\u201361.","DOI":"10.1007\/978-1-4020-9819-2_7"},{"key":"10.1016\/j.ctrv.2011.06.011_b0115","doi-asserted-by":"crossref","unstructured":"Solomou E, Kazanti A, Romanos O, Kardamaki D. Magnetic resonance imaging of metastatic bone disease. In: Kardamakis D, Vassilou V, Chow E, editors. Bone metastases: a translational and clinical approach. Springer; 2009. p. 163\u201381.","DOI":"10.1007\/978-1-4020-9819-2_8"},{"key":"10.1016\/j.ctrv.2011.06.011_b0120","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ctrv.2007.10.002","article-title":"New research findings on zoledronic acid: survival, pain, and anti-tumour effects","volume":"34","author":"Saad","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2011.06.011_b0125","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/sj.bjc.6604382","article-title":"Risks and benefits of bisphosphonates","volume":"98","author":"Coleman","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2011.06.011_b0130","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/ncponc1323","article-title":"Effect of bisphosphonates on pain and quality of life in patients with bone metastases","volume":"6","author":"Costa","year":"2009","journal-title":"Nat Clin Prac Oncol"},{"key":"10.1016\/j.ctrv.2011.06.011_b0135","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non small cell lung carcinoma and other solid tumours","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2011.06.011_b0140","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2011.06.011_b0145","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2011.06.011_b0150","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2011.06.011_b0155","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/cncr.11571","article-title":"Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma","volume":"98","author":"Lipton","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2011.06.011_b0160","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000201931","article-title":"Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone","volume":"76","author":"Christodoulou","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.ctrv.2011.06.011_b0165","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/annonc\/mdn788","article-title":"Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile?","volume":"20","author":"Ayllon","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2011.06.011_b0170","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bone.2008.08.132","article-title":"Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma","volume":"44","author":"Brunello","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.ctrv.2011.06.011_b0175","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10147-008-0868-x","article-title":"Multidisciplinary treatment including sorafenib stabilized the bone metastases of renal cell carcinoma in an immunosupressed renal transplant recipient","volume":"14","author":"Hasegawa","year":"2009","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ctrv.2011.06.011_b0180","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.critrevonc.2006.12.005","article-title":"Critical review: Updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients-May 2006","volume":"62","author":"Weitzman","year":"2007","journal-title":"Critical Rev in Oncol\/Haematol"},{"key":"10.1016\/j.ctrv.2011.06.011_b0185","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/SPC.0b013e32830baac2","article-title":"RANKL inhibition in the treatment of bone metastasis","volume":"2","author":"Lipton","year":"2008","journal-title":"Curr Opin Support Palliat Care"},{"key":"10.1016\/j.ctrv.2011.06.011_b0190","doi-asserted-by":"crossref","unstructured":"Henry DH, Costa L, Goldwasser FJ, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; [Epub ahead of print].","DOI":"10.1016\/j.yonc.2011.07.021"},{"key":"10.1016\/j.ctrv.2011.06.011_b0195","doi-asserted-by":"crossref","unstructured":"Van den Wyngaert T, Wouters K, Huizing MT, Vermorken JB. RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ). Support Care Cancer 2011; [Epub ahead of print].","DOI":"10.1007\/s00520-010-1061-0"},{"key":"10.1016\/j.ctrv.2011.06.011_b0200","first-page":"27","article-title":"Incidence, outcomes of osteonecrosis of the jaw from an integrated analysis of the pivotal randomized double-blind, double-dummy phase 3 trials comparing denosumab, zoledronic acid for treatment of bone metastases in advanced cancer patients or myeloma","volume":"48","author":"Brown","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.ctrv.2011.06.011_b0205","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00432-009-0664-7","article-title":"Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases","volume":"136","author":"\u017bolnierek","year":"2009","journal-title":"J. Cancer Res Clin Oncol"},{"key":"10.1016\/j.ctrv.2011.06.011_b0210","first-page":"5165","article-title":"Efficacy of sunitinib in patients with renal cell carcinoma with bone metastases","volume":"30","author":"Paule","year":"2010","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctrv.2011.06.011_b0215","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/1471-2474-11-145","article-title":"Bone metastases from renal cell carcinoma: patient survival after surgical treatment","volume":"11","author":"Fottner","year":"2010","journal-title":"BMC Musculoskeletal Disorders"},{"key":"10.1016\/j.ctrv.2011.06.011_b0220","doi-asserted-by":"crossref","unstructured":"Leer JWH, van-der-Linden YM. Radiotherapy and bone metastases. In: Kardamakis D, Vassilou V, Chow E, editors. Bone metastases: a translational and clinical approach. Springer; 2009. p. 185\u201393.","DOI":"10.1007\/978-1-4020-9819-2_9"},{"key":"10.1016\/j.ctrv.2011.06.011_b0225","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/1097-0142(19830215)51:4<614::AID-CNCR2820510411>3.0.CO;2-J","article-title":"The role of radiation therapy in the management of metastatic renal cell carcinoma","volume":"51","author":"Halperin","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2011.06.011_b0230","first-page":"133","article-title":"Buzaianu-EM, Damron-TA","volume":"459","author":"Reichel","year":"2007","journal-title":"Radiotherapy to bone has utility in multifocal metastatic renal carcinoma. Clin Orthop Relat Res"},{"key":"10.1016\/j.ctrv.2011.06.011_b0235","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.eururo.2005.11.004","article-title":"Short-course radiotherapy (RT) for metastatic spinal cord compression (MSCC) due to renal cell carcinoma: Results of a retrospective multi-center study","volume":"49","author":"Rades","year":"2006","journal-title":"European Urol"},{"key":"10.1016\/j.ctrv.2011.06.011_b0240","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1464-410X.2008.08124.x","article-title":"Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate","volume":"103","author":"Kijima","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.ctrv.2011.06.011_b0245","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.eururo.2007.03.083","article-title":"Adjuvant therapy with sorafenib in bone-metastases bilateral renal carcinoma: a case report","volume":"52","author":"Sciarra","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2011.06.011_b0250","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S0022-5347(05)64743-X","article-title":"Characterization of a renal cell carcinoma cell line derived from a human bone metastasis and establishment of an experimental nude mouse model","volume":"168","author":"Weber","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.ctrv.2011.06.011_b0255","first-page":"2940","article-title":"Blockade of epidermal growth factor receptor signalling leads to inhibition of renal cell carcinoma growth in the bone of nude mice","volume":"63","author":"Weber","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2011.06.011_b0260","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10585-010-9329-9","article-title":"Characterization of a new renal cell carcinoma bone metastasis mouse model","volume":"27","author":"Strube","year":"2010","journal-title":"Clin Exp Metast"},{"key":"10.1016\/j.ctrv.2011.06.011_b0265","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ctrv.2008.05.001","article-title":"Bone markers and their prognostic value in metastatic bone disease: Clinical evidence and future directions","volume":"34","author":"Coleman","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2011.06.011_b0270","doi-asserted-by":"crossref","first-page":"5059","DOI":"10.1210\/jc.2003-030910","article-title":"Markers of bone remodelling in metastatic bone disease","volume":"88","author":"Fohr","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2011.06.011_b0275","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s10585-008-9202-2","article-title":"MMP-13 is over-expressed in renal cell carcinoma bone metastasis and is induced by TGF-\u03b21","volume":"25","author":"Kominsky","year":"2008","journal-title":"Clin Exp Metast"},{"key":"10.1016\/j.ctrv.2011.06.011_b0280","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotogerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2011.06.011_b0285","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/dji002","article-title":"Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumours","volume":"97","author":"Brown","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl 15","key":"10.1016\/j.ctrv.2011.06.011_b0290","doi-asserted-by":"crossref","first-page":"e16016","DOI":"10.1200\/jco.2009.27.15_suppl.e16016","article-title":"Correlation of N-telopeptide of type I collagen (NTX) with survival and fractures in patients with bone metastases from renal cell carcinoma","volume":"27","author":"Brown","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4C","key":"10.1016\/j.ctrv.2011.06.011_b0295","first-page":"2443","article-title":"Jonas-D, Oremek GM. Value of procollagen type 1 amino-terminal propeptide in patients with renal cell carcinoma","volume":"28","author":"Klepzig","year":"2008","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctrv.2011.06.011_b0300","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/01.blo.0000059580.08469.3e","article-title":"Treatment of osseous metastases in patients with renal cell carcinoma","volume":"409","author":"Jung","year":"2003","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.ctrv.2011.06.011_b0305","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s12094-009-0418-7","article-title":"Prognostic and predictive factors and genetic analysis of early breast cancer","volume":"11","author":"Martin","year":"2009","journal-title":"Clin Trans Oncol"},{"key":"10.1016\/j.ctrv.2011.06.011_b0310","first-page":"139","article-title":"Nasir, Brufsky A, et al.","volume":"3","author":"Bohn","year":"2010","journal-title":"Biomarker profile in breast carcinomas presenting with bone metastasis. Int J Clin Exp Pathol"},{"key":"10.1016\/j.ctrv.2011.06.011_b0315","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/cncr.23566","article-title":"Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers","volume":"113","author":"Crispen","year":"2008","journal-title":"Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.ctrv.2011.06.011_b0320","first-page":"S60","article-title":"Adjuvant and neoadjuvant small-molecule targeted therapy in high-risk renal cell carcinoma","volume":"16","author":"Kapoor","year":"2009","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ctrv.2011.06.011_b0325","first-page":"913","article-title":"Epidermal growth factor receptor and transforming growth factor alpha expression in papillary and nonpapillary renal cell carcinoma: correlation with metastatic behaviour and prognosis","volume":"1","author":"Uhlman","year":"1995","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2011.06.011_b0330","first-page":"889","article-title":"EGFR and VEGFR2 protein expressions in bone metastases of clear cell renal cancer","volume":"27","author":"Badalian","year":"2007","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctrv.2011.06.011_b0335","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00432-007-0215-z","article-title":"Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma","volume":"133","author":"Ramankulov","year":"2007","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ctrv.2011.06.011_b0340","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1158\/0008-5472.CAN-07-6122","article-title":"Macrophage inflammatory protein-1\u03b4: A novel osteoclast stimulating factor secreted by renal cell carcinoma bone metastasis","volume":"68","author":"Kominsky","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2011.06.011_b0345","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/ijc.23637","article-title":"Global analysis of metastasis-associated gene expression in primary cultures from clinical specimens of clear-cell renal-cell carcinoma","volume":"123","author":"Tan","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2011.06.011_b0350","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1177\/172460081002500209","article-title":"Identification of a novel biomarker signature associated with risk for bone metastasis in patients with renal cell carcinoma","volume":"25","author":"Paule","year":"2010","journal-title":"Int J Biol Markers"},{"key":"10.1016\/j.ctrv.2011.06.011_b0355","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.4161\/cc.7.20.6851","article-title":"MicroRNAs as regulators of epithelial-mesenchymal transition","volume":"20","author":"Gregory","year":"2008","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ctrv.2011.06.011_b0360","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/embor.2008.74","article-title":"A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells","volume":"9","author":"Burk","year":"2008","journal-title":"EMBO Reports"},{"key":"10.1016\/j.ctrv.2011.06.011_b0365","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1756-9966-29-90","article-title":"Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy","volume":"29","author":"Slaby","year":"2010","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2011.06.011_b0370","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1586\/14789450.4.3.371","article-title":"Proteomic analysis of bone cancer: a review of current and future developments","volume":"4","author":"Bhattacharyya","year":"2007","journal-title":"Expert Rev Proteomics."},{"key":"10.1016\/j.ctrv.2011.06.011_b0375","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1155\/2006\/728296","article-title":"Biomarkers that discriminate multiple myeloma patients with or without skeletal involvement detected using SELDI-TOF mass spectrometry and statistical and machine learning tools","volume":"22","author":"Bhattacharyya","year":"2006","journal-title":"Disease Markers"},{"key":"10.1016\/j.ctrv.2011.06.011_b0380","first-page":"303","article-title":"Plasma proteomics predicts chemotherapy response in osteosarcoma patients","volume":"25","author":"Li","year":"2011","journal-title":"Oncol Reports"},{"key":"10.1016\/j.ctrv.2011.06.011_b0385","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1158\/1078-0432.1190.11.3","article-title":"The L1 cell adhesion molecule is induced in renal cancer cells and correlates with metastasis in clear cell carcinomas","volume":"11","author":"Allory","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2011.06.011_b0390","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S1470-2045(06)70732-X","article-title":"Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study","volume":"7","author":"Jiang","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2011.06.011_b0395","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.canlet.2008.04.022","article-title":"Serum Amyloid A as an indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma","volume":"269","author":"Ramnkulov","year":"2008","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ctrv.2011.06.011_b0400","doi-asserted-by":"crossref","first-page":"6054","DOI":"10.1158\/0008-5472.CAN-08-0869","article-title":"Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage","volume":"68","author":"Thompson","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2011.06.011_b0405","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.5858\/2009-0373-OA.1","article-title":"PAX-2 is a helpful marker for diagnosing metastatic renal cell carcinoma: comparison with the renal cell carcinoma marker antigen and kidney-specific cadherin","volume":"134","author":"Ozcan","year":"2010","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ctrv.2011.06.011_b0410","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s11033-010-0200-5","article-title":"Expression of stromal-derived factor-1 (SDF-1) and chemokine receptor (CXCR4) in bone metastasis of renal carcinoma","volume":"38","author":"Zhao","year":"2010","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.ctrv.2011.06.011_b0415","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1002\/ijc.23403","article-title":"Metastasis is promoted by a bioenergetic switch: New targets for progressive renal cell cancer","volume":"122","author":"Langbein","year":"2008","journal-title":"Int J Cancer"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573721100123X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573721100123X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T13:52:05Z","timestamp":1712670725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030573721100123X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":83,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S030573721100123X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2011.06.011","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}